What is Zacks Research's Forecast for Surmodics Q3 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Investment analysts at Zacks Research reduced their Q3 2025 earnings per share estimates for Surmodics in a report released on Tuesday, May 27th. Zacks Research analyst D. Dey now anticipates that the company will earn ($0.21) per share for the quarter, down from their prior estimate of ($0.18). The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' Q4 2025 earnings at ($0.16) EPS, FY2025 earnings at ($0.54) EPS, Q1 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.07) EPS and Q2 2027 earnings at $0.11 EPS.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.07). The business had revenue of $28.09 million during the quarter, compared to analysts' expectations of $32.23 million. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%.

SRDX has been the topic of a number of other research reports. Wall Street Zen initiated coverage on Surmodics in a report on Monday, February 3rd. They set a "hold" rating on the stock. Lake Street Capital raised Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price on the stock in a report on Friday, March 7th. Finally, Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.

Surmodics Stock Performance

NASDAQ:SRDX traded down $0.49 during trading hours on Friday, reaching $29.04. 41,419 shares of the stock were exchanged, compared to its average volume of 260,998. The company has a quick ratio of 4.29, a current ratio of 5.45 and a debt-to-equity ratio of 0.26. The firm has a 50 day simple moving average of $28.71 and a 200-day simple moving average of $33.53. Surmodics has a 52 week low of $26.00 and a 52 week high of $42.44. The stock has a market capitalization of $415.24 million, a P/E ratio of -28.75 and a beta of 1.32.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Strs Ohio bought a new stake in shares of Surmodics in the 1st quarter worth approximately $122,000. Murchinson Ltd. lifted its holdings in shares of Surmodics by 5.8% in the 1st quarter. Murchinson Ltd. now owns 52,981 shares of the company's stock worth $1,618,000 after purchasing an additional 2,900 shares during the last quarter. Millennium Management LLC lifted its holdings in shares of Surmodics by 71.6% in the 1st quarter. Millennium Management LLC now owns 206,487 shares of the company's stock worth $6,304,000 after purchasing an additional 86,143 shares during the last quarter. Alpine Global Management LLC lifted its holdings in shares of Surmodics by 70.0% in the 1st quarter. Alpine Global Management LLC now owns 85,000 shares of the company's stock worth $2,595,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Angelo Gordon & CO. L.P. lifted its holdings in shares of Surmodics by 60.0% in the 1st quarter. Angelo Gordon & CO. L.P. now owns 40,000 shares of the company's stock worth $1,221,000 after purchasing an additional 15,000 shares during the last quarter. Institutional investors own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).